STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors

Emmanuel T Akporiaye,Christopher Tucker,Todd Triplett,Kendra Garrison,Lihong Sun,Leona Ling,Andrew Weinberg

Journal for ImmunoTherapy of Cancer（2013）

引用 0|浏览16

暂无评分

摘要

Meeting abstracts OX40 (CD134, TNFRSF4), a member of the tumor necrosis factor receptor (TNFR) superfamily is expressed on activated CD4+ and CD8+ T cells. In pre-clinical tumor models, agonist OX40 antibody (αOX40) therapy is often successful at treating small tumors but is less effective once

查看译文

关键词

Tumor Microenvironment,Tumor Model,Treated Mouse,Tumor Necrosis Factor Receptor,Complete Regression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要